Wall Street analysts expect Stryker Co. (NYSE:SYK) to announce earnings per share (EPS) of $2.16 for the current quarter, according to Zacks Investment Research. Eleven analysts have issued estimates for Stryker’s earnings, with the lowest EPS estimate coming in at $2.14 and the highest estimate coming in at $2.17. Stryker posted earnings of $1.96 per share during the same quarter last year, which would suggest a positive year over year growth rate of 10.2%. The firm is expected to report its next earnings results on Tuesday, January 29th.
According to Zacks, analysts expect that Stryker will report full year earnings of $7.28 per share for the current fiscal year, with EPS estimates ranging from $7.24 to $7.30. For the next fiscal year, analysts expect that the business will report earnings of $8.01 per share, with EPS estimates ranging from $7.89 to $8.14. Zacks’ earnings per share calculations are a mean average based on a survey of sell-side research analysts that cover Stryker.
Stryker (NYSE:SYK) last released its quarterly earnings results on Thursday, October 25th. The medical technology company reported $1.69 earnings per share for the quarter, beating analysts’ consensus estimates of $1.68 by $0.01. The business had revenue of $3.24 billion for the quarter, compared to the consensus estimate of $3.26 billion. Stryker had a net margin of 9.31% and a return on equity of 28.00%.
A number of research analysts have recently weighed in on the stock. Oppenheimer set a $170.00 price target on shares of Stryker and gave the company a “hold” rating in a report on Friday. Canaccord Genuity reiterated a “buy” rating and issued a $185.00 target price on shares of Stryker in a research note on Wednesday, July 25th. Zacks Investment Research upgraded shares of Stryker from a “hold” rating to a “buy” rating and set a $180.00 target price on the stock in a research note on Tuesday, October 30th. Cowen set a $195.00 target price on shares of Stryker and gave the company a “buy” rating in a research note on Friday. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Stryker in a research note on Friday. Seven analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company. The company has an average rating of “Buy” and a consensus price target of $181.81.
In other Stryker news, VP Katherine Ann Owen sold 37,866 shares of the firm’s stock in a transaction on Wednesday, September 5th. The shares were sold at an average price of $166.84, for a total value of $6,317,563.44. Following the sale, the vice president now directly owns 11,367 shares in the company, valued at approximately $1,896,470.28. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP M Kathryn Fink sold 415 shares of the firm’s stock in a transaction on Monday, November 5th. The stock was sold at an average price of $166.56, for a total transaction of $69,122.40. The disclosure for this sale can be found here. Insiders sold a total of 39,031 shares of company stock worth $6,520,313 over the last 90 days. Company insiders own 7.40% of the company’s stock.
Several institutional investors have recently modified their holdings of the company. Canada Pension Plan Investment Board boosted its position in shares of Stryker by 2,573.1% during the 3rd quarter. Canada Pension Plan Investment Board now owns 202,302 shares of the medical technology company’s stock valued at $35,945,000 after acquiring an additional 194,734 shares in the last quarter. Winslow Capital Management LLC boosted its position in shares of Stryker by 215,255.1% during the 3rd quarter. Winslow Capital Management LLC now owns 1,109,079 shares of the medical technology company’s stock valued at $197,061,000 after acquiring an additional 1,108,564 shares in the last quarter. DekaBank Deutsche Girozentrale boosted its position in shares of Stryker by 12.4% during the 3rd quarter. DekaBank Deutsche Girozentrale now owns 226,427 shares of the medical technology company’s stock valued at $38,488,000 after acquiring an additional 25,015 shares in the last quarter. FMR LLC boosted its position in shares of Stryker by 4.8% during the 3rd quarter. FMR LLC now owns 5,581,594 shares of the medical technology company’s stock valued at $991,737,000 after acquiring an additional 253,732 shares in the last quarter. Finally, Blue Fin Capital Inc. boosted its position in shares of Stryker by 13.8% during the 3rd quarter. Blue Fin Capital Inc. now owns 7,047 shares of the medical technology company’s stock valued at $1,252,000 after acquiring an additional 857 shares in the last quarter. Institutional investors and hedge funds own 74.71% of the company’s stock.
Shares of Stryker stock traded down $1.24 during midday trading on Monday, reaching $170.01. 1,254,400 shares of the company’s stock traded hands, compared to its average volume of 1,323,654. The company has a market capitalization of $64.08 billion, a P/E ratio of 26.20, a P/E/G ratio of 2.36 and a beta of 0.64. The company has a current ratio of 1.91, a quick ratio of 1.21 and a debt-to-equity ratio of 0.60. Stryker has a 52 week low of $146.80 and a 52 week high of $179.84.
The business also recently declared a quarterly dividend, which was paid on Wednesday, October 31st. Shareholders of record on Friday, September 28th were given a $0.47 dividend. The ex-dividend date of this dividend was Thursday, September 27th. This represents a $1.88 annualized dividend and a yield of 1.11%. Stryker’s dividend payout ratio is 28.97%.
Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical devices for use in various medical specialties.
Featured Story: How to Profit and Limit Losses With Stop Orders
Get a free copy of the Zacks research report on Stryker (SYK)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.